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Abstract
Background: Five to 22 % of the adult Western population has gallstones. Among them, 13 to 22 % become
symptomatic during their lifetime. Cholecystectomy is the preferred treatment for symptomatic cholecystolithiasis.
Remarkably, cholecystectomy provides symptom relief in only 60-70 % of patients. The objective of this trial is to
compare the effectiveness of usual (operative) care with a restrictive strategy using a standardized work-up with
stepwise selection for cholecystectomy in patients with gallstones and abdominal complaints.
Design and methods: The SECURE-trial is designed as a multicenter, randomized, parallel-arm, non-inferiority trial
in patients with abdominal symptoms and ultrasound proven gallstones or sludge. If patients meet the inclusion
criteria they will be randomized to either usual care or the restrictive strategy.
Patients in the usual care group will be treated according to the physician’s knowledge and preference. Patients in the
restrictive care group will be treated with interval evaluation and stepwise selection for laparoscopic cholecystectomy.
In this stepwise selection, patients strictly meeting the preselected criteria for symptomatic cholecystolithiasis will be
offered a cholecystectomy. Patients not meeting these criteria will be assessed for other diagnoses and re-evaluated at
3-monthly intervals. Follow-up consists of web-based questionnaires at 3, 6, 9 and 12 months.
The main end point of this trial is defined as the proportion of patients being pain-free at 12 months follow-up.
Pain will be assessed with the Izbicki Pain Score and Gallstone Symptom Score.
Secondary endpoints will be the proportion of patients with complications due to gallstones or cholecystectomy,
the association between the patients’ symptoms and treatment and work performance, and ultimately,
cost-effectiveness.
Discussion: The SECURE trial is the first randomized controlled trial examining the effectiveness of usual care versus
restrictive care in patients with symptomatic gallstones. The outcome of this trial will inform clinicians whether a more
restrictive strategy can minimize persistent pain in post-operative patients at least as good as usual care does, but at a
lower cholecystectomy rate. (The Netherlands National Trial Register NTR4022, 17th December 2012)
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Background
Five to 22 % of the adult Western population has
gallstones [1, 2]. Most patients with gallstones remain
asymptomatic. About 13–22 % of the patients with gall-
stones will eventually become symptomatic [3, 4]. Yearly,
this corresponds to approximately 28,000 patients in The
Netherlands and over 800,000 patients in the US [5, 6].
The life time risk of complicated cholecystolithiasis caus-
ing choledocholithiasis, acute cholecystitis, acute pancrea-
titis or cholangitis is 5 % [7]. Removal of the gallbladder
(i.e. cholecystectomy) is the first choice of treatment in
symptomatic cholecystolithiasis [8–10]. Laparoscopic
cholecystectomy is associated with 5.5 % morbidity and
0.2 % mortality [11]. Bile duct injury with an incidence of
0.5–1.0 % is the most severe complication [12]. Despite
the high number of cholecystectomies performed world-
wide, this approach appears to be ineffective for up to
40 % of patients with persistent post-operative pain [13].
The typical presentation of uncomplicated cholecysto-
lithiasis is a biliary colic, consisting of a steady pain,
usually located in epigastrium and/or in the right upper
quadrant, lasting 30 min or longer [14, 15]. However,
the assessment and management of cholelithiasis and
cholecystolithiasis varies between surgeons, hospitals
and countries mainly due to a lack of evidence-based
treatment guidelines [16–18].
Variation in the cholecystectomy rate and differences
in indication for surgery are reported [3, 19, 20]. The
variety in indications for cholecystectomy is hypothe-
sized to be one of the causes for the substantial practice
variation in cholecystectomies in The Netherlands [21].
Dutch health care insurance companies have reported
that the variation in cholecystectomies performed per
100,000 insured inhabitants varied from 48 to 262 pro-
cedures, a fivefold variation. Because LC is a common
surgical procedure mostly performed in regional hospi-
tals, a centralization effect cannot explain this variation.
Moreover, the total number of cholecystectomies in the
Netherlands increased from 12,000 per year in 1990 to
23,000 per year at present, a 100 % increase, whereas the
Dutch population increased from 15 to 17 million
people, an increase of 13 % [5]. The indications for
cholecystectomy are currently not based on evidence
from randomized research and are not restricted within
guidelines. The motivation to perform a cholecystectomy
is not only dependent on an appropriate clinical
indication, but is also influenced by patient preference
and the financial incentive to operate. Patients with per-
sistent pain generate an ongoing and significant health
economic burden for society. Investigating the right
indication for cholecyctectomy is in line with recent
initiatives to improve patient health and reduce risks
and healthcare overuse. [22, 23]
This trial aims to optimize the outcomes of patients with
gallstones and abdominal complaints by identifying which
patients benefit most from surgery for symptomatic chole-
cystolithiasis. This will clarify which patients have an
absolute indication for cholecystectomy and minimize the
proportion of patients undergoing unnecessary cholecystec-
tomy. In this randomized trial usual care will be compared
with a restrictive strategy consisting of a standardized
work-up and stepwise selection for cholecystectomy. This
study will evaluate if stepwise selection for cholecystectomy
is non-inferior to usual care with respect to the proportion
of patients being pain-free after 12 months. We hypothesize
that stepwise selection of patients with cholecystolithiasis
for cholecystectomy is non-inferior to usual care with
respect to the patient reported outcome, but attributes to a
more appropriate use of care and provides a basis for a
lower number of cholecystectomies performed. This may
improve patients’ health status, prevent complications,




The SECURE-trial (Scrutinizing (in)efficient use of
cholecystectomy: a randomized trial concerning vari-
ation in practice) is designed as a multi-center, random-
ized, parallel-arm, non-inferiority study in 1038 subjects
with abdominal symptoms and ultrasound proven
gallstones or sludge. In this multicenter trial 24 centers
are included, located throughout The Netherlands.
Outcomes
The primary endpoint of the SECURE-trial is defined as
the proportion of patients being pain- free at 12 months
follow-up. Pain and pain medication use will be assessed
with the Izbicki Pain Score and Gallstone Symptom Score.
Effectiveness is defined as the proportion of patients
being pain-free at 12 months follow-up.
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Secondary endpoints will be the proportion of patients
with complications due to gallstones or cholecystectomy, the
association between the patients’ symptoms and treatment
and work performance, and ultimately, cost-effectiveness.
Finally practice variation will also be examined with the
variance indicator being defined as the number of patients
undergoing cholecystectomy per 100,000 inhabitants in the
catchment area of the hospital, adjusted for relevant patient
characteristics (i.e. age, sex, socio-economic status).
Study population
Inclusion criteria
The trial will include all patients between the age of 18
and 95 who are referred to a surgical out-patient clinic
with ultra-sound proven gallstones or sludge and ab-
dominal complaints.
Exclusion criteria are (a) a history of complicated
cholelithiasis (i.e., choledocholithiasis, acute cholecystitis,
percutaneous gallbladder drainage, biliary pancreatitis or
cholangitis); (b) an indication for primary open cholecystec-
tomy; (c) a history of current malignancy; (d) an expected
short life span of less than 12 months; (e) an American
Society of Anaesthesiologists physicial status classification
(ASA) of III and IV; (f) known liver cirrhosis; (g) cognitive
disorders that predispose unreliable questionnaire re-
sponses; (h) insufficient knowledge of the Dutch language
and (i) pregnancy.
Study arms
Patients will be randomized to either usual care or to
the restrictive strategy. Inclusion, randomization and
management are illustrated in Fig. 1.
Usual care
Patients assigned to the control group will receive the
usual care given at participating centres. During the first
visit at the surgical out-patient clinic subjects are seen by
a random surgeon, who will assess history, examine the
patient and review investigations. Diagnostic and treat-
ment decisions will be based on the physician’s knowledge,
preference and experience and on the patients’ preferred
choice of treatment. The results of treatment will be
evaluated during one year of follow-up using web-based
questionnaires.
Fig. 1 Flow-chart of the inclusion, randomization and management in the SECURE-trial. *Bilairy colic symtoms are defined as severe steady pain,
lasting 15–30 min or longer, usually located in the epigastrium and/or right upper quadrant
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Restrictive standardized strategy
The restrictive strategy includes a standardized work-up
with stepwise selection for surgery. In this restrictive
arm patients are selected for surgery after a specified
history using a triage instrument based on the Rome
criteria for biliary colic [14, 15] and systematic review of
the literature [24, 25]. According to the Rome criteria a
biliary colic is defined as a severe steady pain, lasting
15–30 min or longer, usually located in the epigastrium
and/or right upper quadrant [14, 15]. The biliary colic
defined according to the Rome criteria has shown to be
insufficiently accurate for the diagnosis of symptomatic
cholecystolithiasis [26]. Systematic reviews of the litera-
ture have shown that three symptoms have a significant
relationship with the diagnosis of symptomatic cholecys-
tolithiasis: biliary colic, pain radiating to the back and a
positive response to simple analgesics [24, 25].
Patients who meet these three criteria: biliary colic
(Rome definition), pain radiating to the back and pain
reduction after analgesics are selected for primary
gallbladder removal. Patients who do not meet all these
criteria go for further work-up of alternative diagnoses
and have an interval evaluation at the outpatient clinic
every three months. This work-up, symptoms and the
effect of therapy aimed at another likely diagnosis are
repeatedly evaluated every three months during one year
of follow-up using web-based questionnaires. At each of
the evaluation moments the indication for surgery can
be made or conservative approach is continued
The use of diagnostics (e.g., gastroscopy) or therapeutics
(e.g., analgesics or antacids) aimed to diagnose or treat
other possible diseases causing the abdominal symptoms
are left to the discretion of the treating physician.
Randomization
Patients will be randomized 1:1 between the usual care
group and the restrictive care group. Randomization will be
computer- and web-based using stratification to ensure a
balanced distribution of (un-)known possible confounders
in both treatment groups, and in blocks of variable size.
Randomization will be stratified according to the fol-
lowing characteristics: center, sex and body mass index.
To ensure allocation concealment the randomization list
will be generated using an online computer software pro-
gram (ALEA NKI-AVL, Amsterdam, The Netherlands, Re-
lease: 2.2.) and implemented into a web-based application.
Sample Size
For the power analysis we assumed that the percentage of
pain-free patients in the restrictive arm will be at least
equal to the usual care arm at the end of follow-up. For
the calculation we assumed, based on literature, that after
usual care a maximum of 80 % of patients will be pain-
free [13]. If the restrictive strategy results in less than 75 %
of patients pain-free, then this strategy will not be consid-
ered non-inferior. However, it is hypothesized that the
percentage of pain-free patients in the restrictive strategy
group will be slightly higher than the percentage in the
usual care arm and rise to 82 % or above.
If the usual care arm becomes, to some extent, contami-
nated by the restrictive strategy arm, then the 80 % pain-
free estimate for the usual care arm will tend towards the
82 % for the restrictive standardized work-up arm. If so,
the boundary of non-inferiority should be increased as
well in order to maintain the non-inferiority of 5 %.
Hence, if contamination would result in 81 % of pa-
tients pain-free in the usual care arm, then the lower
boundary of non-inferiority equals 76 %. Although we
do not expect contamination to happen, it is accounted
for in this calculation of the sample size. Thus, with a
one-sided Z test, 80 % power and a significance level
of 5 % a total of 1038 evaluable patients (519 in each
arm) needs to be included, if the boundary of non-
inferiority equals 76 %. In the absence of contamin-
ation and a lower boundary of non-inferiority of 75 %,
this total number of 1038 evaluable patients will result
in a power of 89 %.
Cost-effectiveness
The economic evaluation will be undertaken as a cost-
effectiveness analysis (CEA) with the costs per patient
pain-free at 12 months as primary outcome measure.
Additionally, a cost-utility analysis (CUA) will be per-
formed with the costs per quality adjusted life-year
(QALY) as outcome. Both analyses will be performed
from a societal perspective and the time horizon is set at
12 months.
Questionnaires
Patients can complete the questionnaires through the
trial website or they can complete a paper copy.
The questionnaire set consists of four parts and will
be completed at baseline and at 3, 6, 9 and 12 months of
follow-up:
 The EuroQol 5 Dimensions (EQ-5D) combined
with a Short-Form Health and Labour Questionnaire
(SF-HLQ) [27]: The EQ-5D is a generic questionnaire
and covers five domains of health (mobility, self-care,
usual activities, pain/discomfort and anxiety/depres-
sion). The SF-HLQ contains three modules covering
absence from paid employment, production loss with-
out absence from paid employment and impediments
to paid of unpaid employment. Additional questions
assess health care consumption based on home,
primary and secondary care consultations, emergency
department and hospital admissions, medication use
and out-of-pocket costs.
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 The Gastrointestinal Quality of Life Index (GIQLI)
[28]: This questionnaire includes both specific
questions on gastrointestinal symptoms, for both the
upper and lower digestive tracts, as well as generic
questions on physical, emotional and social
capabilities.26,27 The GIQLI includes 5 domains:
symptoms, physical dysfunction, emotional
dysfunction, social dysfunction and treatment-
related stress
 The Izbicki Pain Score (IPS) [29]: This questionnaire
is designed for upper abdominal pain and based on
four questions regarding frequency of pain, intensity
of pain (as indicated by a visual analogue score), use
of analgesics and disease-related inability to work.
 The Gallstone Symptom List [30]: This specific pain
score was designed and previously used in a large
cohort of patients in the United Kingdom. This
score was designed to asses symptoms associated
with symptomatic cholecystolithiasis.
Safety monitoring
An independent data and safety monitoring committee
(DSMC) will be established. This committee will be
guided by a charter defining their role and responsibil-
ities, and methods specific to the committee. The DSMC
will assess safety by analysis of the complication ratio
due to surgery or due to the gallstones in both study
arms after 50 % of the patients are included. The DSMC
will perform safety assessments consisting of the analysis
of proportion of complications due to cholecystectomy
in the total number of complications. The choice of ap-
propriate statistical technique, if any, will be left to the
discretion of the DSMC, but may consist of a regression
analysis on the proportion of complications due to
cholecystectomy, with treatment and the proportion of
patients with cholecystectomy as covariates. The DMC
will advise the study group to continue, to adapt or to
terminate the study.
Statistical anlysis
Analyses will be carried out according to the intention-
to-treat principle as well as the per protocol principle.
For continuous data, Student’s t-test will be used to
calculate differences between groups for normally dis-
tributed data or Mann-Whitney U test for non-normally
distributed data. The χ2 test will be used to compare
dichotomized outcomes between the groups.
The generalized estimating equations (GEE) will be
used to examine the impact of (i) centre, sex and weight
on the probability of being pain-free at 12 months post-
randomisation, and (ii) treatment strategy, centre, sex
and weight on the number of cholecystectomies. This
procedure extends standard regression analysis, taking into
account the correlation between measurements. To assess
the relation between specific symptoms or sets of symp-
toms and being pain-free at 12 months post-randomisation,
logistic regression analyses will be performed. Data on
quality of life will be assessed by repeated measurement
analysis using a linear mixed model. In all analyses, statis-
tical uncertainties are expressed in 95 % two-sided confi-
dence intervals. A p-value of <0.05 will indicate statistical
significance.
Ethical consideration and informed consent
This trial will be conducted in accordance with the prin-
ciples of the Declaration of Helsinki and as stated in the
laws governing human research in the Netherlands and
Good Clinical Practice. The Medical Ethical Committee
(MEC) of the Academic Medical Center Amsterdam and
local ethical committees of all participating centres have
approved this protocol.
This protocol was endorsed by the board of directors
of each participating hospital prior to the inclusion of
subjects at the respective hospital.
Informed consent will be obtained from each participat-
ing patient in oral and written form prior to randomization.
Discussion
Rationale of study design
In the present study we chose a pragmatic approach to in-
vestigate the effectiveness of a more restrictive care strat-
egy for patients with cholecystolithiasis. The parallel-arm,
non-inferiority study design best fits the focus of research
in which optimal patient selection (identifying the right
patient for the right treatment) rather than treatment ef-
fectiveness (identifying the best treatment given the right
patient) is studied; estimates of both, the proportion of pa-
tients in whom unnecessary cholecystectomies can be pre-
vented as well as the resulting overall effectiveness at the
group level, automatically follow from this design. The
current study design of randomizing patients to usual care
or the restrictive standardized work-up does not exhibit
the weaknesses of alternative designs which were consid-
ered. First, a design with randomization of patients to
laparoscopic cholecystectomy or no surgery would focus
exclusively on the effect of surgery itself and would be in
need of a well-defined target population as reflected in
selective inclusion and exclusion criteria. Such design
would ignore the core issue in this proposal that practice
variation and overconsumption of care result from the
presence of indeterminate means of patient selection and
indication. Second, a cluster randomized design with
hospitals (rather than patients) randomized to usual care
or to the restrictive standardized work-up would run the
risk of selection bias and confounding. Selection bias in a
cluster randomized trial might occur, if the local recruitment
of patients would be influenced by prior knowledge of the
treatment strategy offered by the hospital; confounding
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following an uneven distribution of hospitals with similar
characteristics over both trial arms might easily occur
given the number of participating hospitals. In addition,
an adequate informed consent procedure for such cluster
randomized trial would be difficult to accomplish.
A potential pitfall of the present design is the risk of
contamination of usual care by the restrictive standard-
ized work-up approach as it is conceivable that special-
ists transfer their experience with this work-up to usual
care. It should be noted however that the equipoise
principle still holds for usual care and the standardized
work-up. It is very unwise and perhaps even unethical to
adjust usual care as long as the clinical non-inferiority
and health economic superiority of the restrictive stan-
dardized work-up approach has not been demonstrated
yet. The equipoise principle should make surgeons in
the participating hospitals indifferent regarding their
preference for either approach during the study period.
Moreover many different surgeons are involved making
a strong and uniform contamination effect unlikely.
To further counter the risk of contamination as well as
its potential impact on the study results, we will monitor
each step during usual care in the clinical report forms.
Additionally, a sample size is calculated conditional on the
presence of contamination, which will be reevaluated
during interim analysis and adjusted if indicated.
To optimally reflect the current health care practice all
patients with abdominal pain and gallstones are included
in this study. Pre-selection by excluding patients with
non-specific abdominal symptoms and only including
patients with specific “biliary colic” would potentially
optimize health care practice outcome, but would leave
optimization efforts unmeasured and would give no
insight in the obvious difficulty of this selection. Selected
inclusion would certainly hamper the future implemen-
tation of results by leaving the dispute unresolved of
which symptoms are typical and which are not. This will
risk non-compliance to new guidelines as these would
not reflect real life. The ‘typical’ gallstone colic patients
are less typical than definition suggests. Even if a colic
resulting from gallstones is almost certain, then still,
wide differences of opinion exist between surgeons of
how many colics are needed and which time interval be-
tween colics should have presented to indicate surgery.
Impact of the secure trial
Both the inefficacy of cholecystectomy in a considerable
number of patients as well as a substantial practice vari-
ation in gallbladder surgery warrant a more evidence-
based approach for this high volume procedure. The first
challenge in evaluating patients with upper abdominal
symptoms found to have gallstones is to determine
whether the stones are the cause of the symptoms or
merely an incidental finding.
There is no national or international prospective random-
ized study of the efficiency gains of a standardized work-up
and interval evaluation with stepwise selection for laparo-
scopic cholecystectomy. The best available patient reported
data comes from the long term follow up from a random-
ized study which showed that a watchful waiting strategy
was shown to be a feasible option in 31 % of patients with
uncomplicated symptomatic cholelithiasis during 14 years
of follow-up [31]. In the absence of existing evidence it is
clear that a more adequate discriminative selection tool for
cholecystectomy is necessary. The present study aims to
improve the outcome of patients with gallstones and
abdominal complaints by identifying those patients with an
absolute indication for cholecystectomy based on an accur-
ate assessment of symptomology. This will ultimately maxi-
mise the number of patients successfully treated for biliary
pain and minimise not only patients with persistent post
cholecystectomy pain, but also the risks of unnecessary
operative intervention. Secondly, this study examines the
cost-effectiveness and budgetary impact of a more restrict-
ive strategy for cholecystectomy against usual care for
patients with abdominal complaints and gallstones. In the
present trial an evaluation will be performed on whether a
restrictive strategy with standardized work-up, interval
evaluation and stepwise selection for surgery can improve
patient outcomes with a reduced number of cholecystecto-
mies. Results of the present study as proposed here will
affect health care policy concerning cholecystectomy for
the coming decades.
Conclusion
The SECURE-trial is a multicentre trial designed to assess
the effectiveness of a more restrictive treatment strategy
in patients with gallstones and abdominal complaints,
using a restrictive standardized work-up with stepwise
selection for cholecystectomy. This trial aims to improve
the outcome of patients after cholecystectomies by opti-
mizing the indications for cholecystectomy. Therefore, the
SECURE-trial has the potential to impact daily clinical
practice and the development of national and potentially
international guidelines concerning the indications for
cholecystectomy in symptomatic gallstone disease.
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